Tang Capital Management LLC boosted its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 3.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,997,399 shares of the company's stock after purchasing an additional 150,000 shares during the quarter. Evolus comprises about 3.7% of Tang Capital Management LLC's holdings, making the stock its 4th biggest position. Tang Capital Management LLC owned 7.89% of Evolus worth $55,171,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently made changes to their positions in the company. KBC Group NV bought a new stake in shares of Evolus during the fourth quarter worth about $49,000. IFP Advisors Inc increased its stake in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after purchasing an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Evolus in the fourth quarter valued at $106,000. Rafferty Asset Management LLC purchased a new stake in Evolus during the fourth quarter valued at about $115,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Evolus during the 4th quarter valued at approximately $118,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Evolus news, insider David Moatazedi sold 15,787 shares of Evolus stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $9.87, for a total transaction of $155,817.69. Following the transaction, the insider now directly owns 492,832 shares of the company's stock, valued at approximately $4,864,251.84. This trade represents a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rui Avelar sold 27,904 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the sale, the insider now directly owns 362,467 shares of the company's stock, valued at $4,806,312.42. This trade represents a 7.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 86,241 shares of company stock worth $1,048,666 in the last quarter. 5.90% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
EOLS has been the subject of a number of recent analyst reports. BTIG Research started coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 target price for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Thursday, May 8th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Finally, Barclays increased their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $23.75.
Check Out Our Latest Research Report on EOLS
Evolus Price Performance
Shares of EOLS traded down $0.37 during midday trading on Wednesday, reaching $9.59. The stock had a trading volume of 685,842 shares, compared to its average volume of 690,631. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The company has a market capitalization of $618.32 million, a price-to-earnings ratio of -10.54 and a beta of 1.11. The company's 50-day moving average is $11.19 and its 200 day moving average is $12.24. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82.
Evolus Company Profile
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Articles
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
